[MeMed in GlobeNewsWire] Prospective Study Finds Potential Utility of MeMed’s Host Immune Technology for Personalizing Treatment of Severe COVID-19 Patients

Researchers at Israel’s Rabin Medical Center (comprised of Beilinson and Hasharon Hospitals) in collaboration with MeMed, have published prospective data on the potential utility of the analysis of IP-10, a host immune biomarker, in managing the care and treatment of patients with severe COVID-19 infection.

Read more here.

The post [MeMed in GlobeNewsWire] Prospective Study Finds Potential Utility of MeMed’s Host Immune Technology for Personalizing Treatment of Severe COVID-19 Patients appeared first on OurCrowd Blog.

OurCrowd Blog

Covid 19 Analysis On Immune Anti-Inhibitor Market Analysis, Strategic Assessment, Trend Outlook and Business Opportunities 2020-2027 | Shire Plc, Baxter International, Inc, F. Hoffmann La Roche Ltd., Novo Nordisk A/S, and CSL Behring. – Oenga

Covid 19 Analysis On Immune Anti-Inhibitor Market Analysis, Strategic Assessment, Trend Outlook and Business Opportunities 2020-2027 | Shire Plc, Baxter International, Inc, F. Hoffmann La Roche Ltd., Novo Nordisk A/S, and CSL Behring.  Oenga
“nigeria startups when:7d” – Google News

Immunai Raises $20M to Provide a Complete Understanding of the Immune System With Single Cell Profiling

The human immune system is a complex network made up of cells, proteins, and organs that protect your body. Advances in technology have allowed researchers, scientists, and physicians to understand this sophisticated system like never before. Immunai, cofounded by Noah Solomon, leverages machine learning and artificial intelligence to provide a complete profile of the immune system. The company just launched from stealth with a fresh $ 20M in funding. Noah shares with us how Immunnaii is building the largest database for immunology.
AlleyWatch

Predicting immune system with AI: US-Israeli biotech startup Immunai scores €18.5M funding

Immunai is a biotech company that’s on a mission to fully map the immune system to better detect, diagnose, and treat disease by advancing personalised medicine through a comprehensive understanding of the immune system. 

Raised €18.5 million!

Recently, the company has raised $ 20 million (approx €18.5 million) in seed funding, which will be used to further the development of its technology and business functions while expanding its team of scientists, engineers, and machine learning experts.

The funding round was led by Viola Ventures and TLV Partners, and have established clinical partnerships with over 10 medical centers, as well as multiple commercial partnerships with cell therapy and checkpoint blockade with biopharma companies.

Minor variation in cell therapy influences patient’s response significantly

Due to the incredible complexity of the immune system, trillions of its cells are partitioned into hundreds of cell types and states, and how they interplay with other cells and proteins is prohibitively hard to predict and also how drugs will affect immune cells. For cell therapies with high manufacturing costs, a slight variation in cell therapy products can have a significant influence on a patient’s response to the therapy. 

Vertically-integrated platform!

The New York-headquartered company has developed a vertically-integrated platform for multi-omic single-cell profiling that offers a broader view of the immune system in states of health, disease, and treatment to examine the body’s response to a stimulus. 

Identify more subtle nuances!

With Immunai’s platform, pharmaceutical companies can identify more subtle nuances in cell abundances and cell function and mechanisms of action and biomarkers for toxicity response to accurately measure the efficacy of immunotherapies. 

For cell therapies, in particular, Immunai partners with cell therapy companies to understand cellular products’ sub-populations in unprecedented detail before and after infusion. 

Noam Solomon, CEO of Immunai:

”When looking at only a specific disease or patient cohort, one gets a limited and siloed view of the immune system. “By using machine learning and applying it to our proprietary diverse database of single-sequencing data paired with rich clinical data, our platform identifies common patterns that are not visible when looking at the narrower disease-specific view.” 

How it works:

  • Immunai leverages single-cell technologies to profile cells at unprecedented scale and depth – deriving over a terabyte of data from a single blood sample.
  • Its proprietary database and machine learning algorithms map incoming data to hundreds of cell types and states to create immune profiles based on highlighting differentiated elements.
  • The database of immune profiles supports biomarker discovery and insight generation to help answer important questions about the immune system by identifying subtle changes in cell type and state-specific expression and helping distinguish that from normal expression.

Founded in 2018 by ex-Harvard-MIT postdoc Researcher, CEO Noam Solomon and ex-MIT and Palantir ML Engineer, CTO Luis Voloch, the company is headquartered in New York and has offices in San Francisco and Tel Aviv. 

Voloch, said:

“Our mission is to map the immune system with neural networks and transfer learning techniques informed by deep immunology knowledge. We developed the tools and knowhow to help every immuno-oncology and cell therapy researcher excel at their job. This helps increase the speed in which drugs are developed and brought to market by elucidating their mechanisms of action and resistance.”

Main image credits: Immunai

Stay tuned to Silicon Canals for more European technology news

The post Predicting immune system with AI: US-Israeli biotech startup Immunai scores €18.5M funding appeared first on Silicon Canals .

Startups – Silicon Canals